In a randomized, double-blind, placebo-controlled, crossover study, the effect of alfuzosin 10mg on BP and HR was evaluated in 14 male volunteers (mean age: 28 yr; range: 24–30). BP<135/85 obtained in two separated measurements was a main inclusion criterion. Patients were then randomized to alfuzosin (10mg once a day) or placebo for 1 wk, followed by a washout week, and then crossed over to the other treatment. Patients were instructed to self-measure systolic (SBP) and diastolic (DBP) blood pressure and HR every hour between 8am and 8pm during the first and the last day of each cycle treatment.

All 14 enrolled volunteers completed the study. No significant difference in either SBP, DBP, or HR was observed between the placebo and alfuzosin groups at baseline. Alfuzosin did not affect SBP, DBP, or HR. No hypotensive episode (SBP reduction >10%) was recorded during each treatment.

This study shows that alfuzosin 10mg is well tolerated by young healthy subjects and may therefore be safely administered to young normotensive patients affected by distal ureteral stones and prostatitis.

Nicola Mondaini^a, Gianluca Giubilei^b, Andrea Ungar^c, Paolo Gontero^d, Tommaso Cai^a, Andrea Gavazzi^a, Riccardo Bartoletti^a, Pierangelo Geppetti^c, Marco Carini<sup>b

a</sup> Urology Division, S. Maria Annunziata Hospital, University of Florence, Florence, Italy
^b Section of Urology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy
^c Section of Geriatrics, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy
^d Department of Urology, University of Novara, Novara, Italy

Accepted 12 June 2006 published online 28 June 2006.